Akari Therapeutics enters preclinical ADC research collaboration with Whitehawk Therapeutics

Reuters2026/07/21 11:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to run preclinical studies on dual-payload ADCs.
Work will test Akari’s PH1 RNA-splicing payload in combination with Whitehawk’s topoisomerase I inhibitor ADC platform for compatibility and synergy.
Akari will lead study design, execution, evaluation; both companies will jointly review results to guide potential broader development talks.
Collaboration starts immediately; interim data updates are expected as the studies progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210705PRIMZONEFULLFEED9765042) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Akari Therapeutics enters preclinical ADC research collaboration with Whitehawk Therapeutics

You may also like

Crypto prices